AssetMark’s Citius Pharmaceuticals CTXR Stock Holding History
Bought
Maintained
Sold
Other funds holding CTXR
BFCFS
AssetMark's CTXR Position: Q3 2026 in Review
AssetMark sold out of Citius Pharmaceuticals (CTXR) in Q3 2026, closing a stake of 372 shares — an estimated $225 sold.
AssetMark first reported a position in CTXR in Q1 2026 and held it in 2 quarters. The position peaked at $335 in Q1 2026. 27 funds tracked by Wall St. Rank hold CTXR as of Q3 2026.
- AssetMark reported no remaining Citius Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
- AssetMark sold 372 Citius Pharmaceuticals shares in Q3 2026, an estimated $225.
- AssetMark first reported a position in Citius Pharmaceuticals in Q1 2026 and held it in 2 quarters.
- AssetMark's Citius Pharmaceuticals position peaked at $335 in Q1 2026.
- 27 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.